Cargando…
Rolling out new anti-tuberculosis drugs without diagnostic capacity
Deaths from tuberculosis (TB) reached over 1.6 million in 2021 with 10.6 million people becoming ill. Multidrug-resistant TB, defined as the Mycobacterium tuberculosis organism having resistance to at least isoniazid and rifampicin, represented 3.9% of new TB cases and 18% of previously treated case...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365078/ https://www.ncbi.nlm.nih.gov/pubmed/37492347 http://dx.doi.org/10.1183/20734735.0084-2023 |
_version_ | 1785076976204120064 |
---|---|
author | Ness, Tara Van, Le Hong Petermane, Ilze Duarte, Raquel Lange, Christoph Menzies, Dick Cirillo, Daniela Maria |
author_facet | Ness, Tara Van, Le Hong Petermane, Ilze Duarte, Raquel Lange, Christoph Menzies, Dick Cirillo, Daniela Maria |
author_sort | Ness, Tara |
collection | PubMed |
description | Deaths from tuberculosis (TB) reached over 1.6 million in 2021 with 10.6 million people becoming ill. Multidrug-resistant TB, defined as the Mycobacterium tuberculosis organism having resistance to at least isoniazid and rifampicin, represented 3.9% of new TB cases and 18% of previously treated cases. While new drug regimens continue to be developed and introduced to improve treatment of drug-resistant forms of TB, diagnostic capability to identify drug resistance lags woefully behind. While significant mortality benefits exist for these newer drug regimens, implementing them without proper drug resistance diagnostic capacity could lead to development of more drug resistances and exhaust these new therapeutic tools. Moving forward, the roll-out of new TB drugs and regimens must be paired with implementation of diagnostics to ensure judicious use of resources and the best chance for improving TB worldwide. |
format | Online Article Text |
id | pubmed-10365078 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-103650782023-07-25 Rolling out new anti-tuberculosis drugs without diagnostic capacity Ness, Tara Van, Le Hong Petermane, Ilze Duarte, Raquel Lange, Christoph Menzies, Dick Cirillo, Daniela Maria Breathe (Sheff) Viewpoint Deaths from tuberculosis (TB) reached over 1.6 million in 2021 with 10.6 million people becoming ill. Multidrug-resistant TB, defined as the Mycobacterium tuberculosis organism having resistance to at least isoniazid and rifampicin, represented 3.9% of new TB cases and 18% of previously treated cases. While new drug regimens continue to be developed and introduced to improve treatment of drug-resistant forms of TB, diagnostic capability to identify drug resistance lags woefully behind. While significant mortality benefits exist for these newer drug regimens, implementing them without proper drug resistance diagnostic capacity could lead to development of more drug resistances and exhaust these new therapeutic tools. Moving forward, the roll-out of new TB drugs and regimens must be paired with implementation of diagnostics to ensure judicious use of resources and the best chance for improving TB worldwide. European Respiratory Society 2023-06 2023-07-11 /pmc/articles/PMC10365078/ /pubmed/37492347 http://dx.doi.org/10.1183/20734735.0084-2023 Text en Copyright ©ERS 2023 https://creativecommons.org/licenses/by-nc/4.0/Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. |
spellingShingle | Viewpoint Ness, Tara Van, Le Hong Petermane, Ilze Duarte, Raquel Lange, Christoph Menzies, Dick Cirillo, Daniela Maria Rolling out new anti-tuberculosis drugs without diagnostic capacity |
title | Rolling out new anti-tuberculosis drugs without diagnostic capacity |
title_full | Rolling out new anti-tuberculosis drugs without diagnostic capacity |
title_fullStr | Rolling out new anti-tuberculosis drugs without diagnostic capacity |
title_full_unstemmed | Rolling out new anti-tuberculosis drugs without diagnostic capacity |
title_short | Rolling out new anti-tuberculosis drugs without diagnostic capacity |
title_sort | rolling out new anti-tuberculosis drugs without diagnostic capacity |
topic | Viewpoint |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365078/ https://www.ncbi.nlm.nih.gov/pubmed/37492347 http://dx.doi.org/10.1183/20734735.0084-2023 |
work_keys_str_mv | AT nesstara rollingoutnewantituberculosisdrugswithoutdiagnosticcapacity AT vanlehong rollingoutnewantituberculosisdrugswithoutdiagnosticcapacity AT petermaneilze rollingoutnewantituberculosisdrugswithoutdiagnosticcapacity AT duarteraquel rollingoutnewantituberculosisdrugswithoutdiagnosticcapacity AT langechristoph rollingoutnewantituberculosisdrugswithoutdiagnosticcapacity AT menziesdick rollingoutnewantituberculosisdrugswithoutdiagnosticcapacity AT cirillodanielamaria rollingoutnewantituberculosisdrugswithoutdiagnosticcapacity |